FTO (intracellular; human) EIA Kit (DEIA5087)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

cell lysates
Species Reactivity
Intended Use
CD's FTO (intracellular; human) EIA Kit is an immunometric assay which can be used to measure FTO in human cell lysates. The assay exhibits a detection limit of 50 pg/mL and an assay range of 0-10 ng/mL.
Contents of Kit
1. Anti-FTO (human) Precoated 96-Well Strip Plate, 1 plate
2. Wash Buffer Concentrate (10x), 1 vial/50 mL
3. Dilution Buffer (5X), 1 vial/50 mL
4. Detection Antibody, 1 vial/12 mL
5. Anti-Rabbit IgG/HRP Conjugate (100x), 1 vial/150 μL
6. FTO (human) EIA Standard, 1 vial
7. Substrate Solution, 1 vial/12 mL
8. Stop Solution, 1 vial/12 mL
9. Quality Control Sample, 1 vial
10. Lysis Buffer Concentrate (10x), 1 vial/12 mL
Store the unopened kit at 4°C upon receipt and when it is not in use. For more detailed information, please download the following document on our website.
50 pg/mL


Have you cited DEIA5087 in a publication? Let us know and earn a reward for your research.

Related Products

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Gene Signature and Identification of Clinical Trait-Related m(6)A Regulators in Pancreatic Cancer


Authors: Hou, Jie; Wang, Zhan; Li, Hong; Zhang, Hongzhi; Luo, Lan

Pancreatic cancer (PC) has a very poor prognosis and is usually diagnosed only at an advanced stage. The discovery of new biomarkers for PC will help in early diagnosis and a better prognosis for patients. Recently, N6-methyladenosine (m(6)A) RNA modifications and their regulators have been implicated in the development of many cancers. To investigate the functions and mechanisms of m(6)A modifications in the development of PC, 19 m(6)A regulators, including m(6)A-methyltransferases (ZC3H13, RBM15/15B, WTAP, KIAA1429, and METTL3/14), demethylases (FTO and ALKBH5), and binding proteins (YTHDF1/2/3, YTHDC1/2, IGF2BP1/2/3, HNRNPC, and HNRNPA2B1) were analyzed in 178 PC tissues from the cancer genome atlas (TCGA) database. The results were verified in PC cell lines Mia-PaCa-2, BXPC-3, and the control cell line HDE-CT. The m(6)A regulators-based sample clusters were significantly related to overall survival (OS). Further, lasso regression identified a six-m(6)A-regulator-signature prognostic model (KIAA1429, HNRNPC, METTL3, YTHDF1, IGF2BP2, and IGF2BP3). Model-based high-risk and low-risk groups were significantly correlated with OS and clinical traits (pathologic M, N, and clinical stages and vital status). The risk signature was verified as an independent prognostic marker for patients with PC. Finally, gene set enrichment analysis revealed m(6)A regulators (KIAA1429, HNRNPC, and IGF2BP2) were related to multiple biological behaviors in PC, including adipocytokine signaling, the well vs. poorly differentiated tumor pathway, tumor metastasis pathway, epithelial mesenchymal transition pathway, gemcitabine resistance pathway, and stemness pathway. In summary, the m6A regulatory factors which related to clinical characteristics can be involved in the malignant progression of PC, and the constructed risk markers may be a promising prognostic biomarker that can guide the individualized treatment of PC patients.

RbF modified FTO electrode enable energy -level matching for efficient electron transport layer -free perovskite solar cells


Authors: Huang, Shuai; Dong, Qingshun; Shi, Yantao; Duan, Lian; Wang, Liduo

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket